Media stories about Capnia (NASDAQ:SLNO) have been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Capnia earned a news impact score of 0.16 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.6770825037236 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of Capnia (NASDAQ SLNO) traded up $0.03 during midday trading on Tuesday, reaching $1.43. 5,000 shares of the company were exchanged, compared to its average volume of 24,596. Capnia has a 52-week low of $1.32 and a 52-week high of $6.60.
A number of equities analysts have weighed in on the stock. Maxim Group reaffirmed a “buy” rating and issued a $25.00 target price on shares of Capnia in a research note on Wednesday, September 13th. dropped their price target on shares of Capnia from $25.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, November 15th. Finally, ValuEngine raised shares of Capnia from a “strong sell” rating to a “sell” rating in a research note on Friday, October 6th.
WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Capnia (SLNO) Stock Price” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://ledgergazette.com/2017/12/05/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-capnia-slno-stock-price.html.
Capnia Company Profile
Soleno Therapeutics, Inc, formerly Capnia, Inc, is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief.
Receive News & Ratings for Capnia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capnia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.